Metabolic Advantage of 25(OH)D3 versus 1,25(OH)2D3 Supplementation in Infantile Nephropathic Cystinosis-Associated Adipose Tissue Browning and Muscle Wasting

Cells. 2022 Oct 17;11(20):3264. doi: 10.3390/cells11203264.

Abstract

Manifestations of infantile nephropathic cystinosis (INC) often include cachexia and deficiency of circulating vitamin D metabolites. We examined the impact of 25(OH)D3 versus 1,25(OH)2D3 repletion in Ctns null mice, a mouse model of INC. Six weeks of intraperitoneal administration of 25(OH)D3 (75 μg/kg/day) or 1,25(OH)2D3 (60 ng/kg/day) resulted in Ctns-/- mice corrected low circulating 25(OH)D3 or 1,25(OH)2D3 concentrations. While 25(OH)D3 administration in Ctns-/- mice normalized several metabolic parameters characteristic of cachexia as well as muscle function in vivo, 1,25(OH)2D3 did not. Administration of 25(OH)D3 in Ctns-/- mice increased muscle fiber size and decreased fat infiltration of skeletal muscle, which was accompanied by a reduction of abnormal muscle signaling pathways. 1,25(OH)2D3 administration was not as effective. In conclusion, 25(OH)D3 supplementation exerts metabolic advantages over 1,25(OH)2D3 supplementation by amelioration of muscle atrophy and fat browning in Ctns-/- mice.

Keywords: 1,25(OH)2D3; 25(OH)D3; adipose tissue browning; cachexia; infantile nephropathic cystinosis; muscle wasting; vitamin D insufficiency.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adipose Tissue / metabolism
  • Animals
  • Cachexia* / metabolism
  • Calcitriol* / pharmacology
  • Calcitriol* / therapeutic use
  • Dietary Supplements
  • Mice
  • Mice, Knockout
  • Muscle, Skeletal / metabolism
  • Muscular Atrophy / drug therapy
  • Muscular Atrophy / metabolism
  • Vitamin D / metabolism
  • Vitamin D / pharmacology
  • Vitamin D / therapeutic use

Substances

  • Calcitriol
  • 25-hydroxyvitamin D
  • Vitamin D

Supplementary concepts

  • Cystinosis, Infantile Nephropathic

Grants and funding

This investigation was supported by Cystinosis Research Foundation. P.Z. was supported by the following fundings—“Chunhui Plan” Cooperative Scientific Research Project, Ministry of Education of the People’s Republic of China (HLJ2019023), 2022 Key R&D Plan of Science and Technology Department of Sichuan Province (2022YFS0149), Science and Technology Fund of Chengdu Medical College in 2021 (CYZYB21-22), Medical Research Project of Sichuan Province in 2021, Sichuan Medical Association (S21037) and Medical Research Project of Chengdu Municipal Health Commission (2022113).